Skip to main contentSkip to footer

PIPELINE

PIPELINE

si-544 is a phase 2 ready asset with multiple indication expansion opportunities

Pipeline – selectION Therapeutics

One drug – multiple indications

T cell-driven autoimmunity spans 80+ diseases and affects up to 50M people in the US alone. Due to its unique, disease-modifying, mechanism of action si-544 has the potential to positively impact them all. 
Common T cell-mediated autoimmune diseases include Atopic Dermatitis, Psoriasis, Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease, Lupus Nephritis, Vasculitis, and many other indications.

Interested in collaborating to advance disease-modifying therapies for autoimmune disease?

CONTACT US

CLINICAL TRIALS

Clinical Data

First-in-human results (atopic dermatitis)

si-544 sets new benchmark for safety & tolerability with subjects maintaining full immunocompetence. Plasma levels clinically achieved allow for virtually full target engagement

FIH study: A multi-center, Phase 1b, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, and efficacy of si-544 in adults with atopic dermatitis (NCT05383378 / EUCT 2021-003061-35)

Proof-of-Concept (psoriasis)

Short 4-week treatment cycle resulted in statistically significant clinical improvement as measured by percentage change in Psoriasis Activity and Severity Index (PASI)

PoC study: A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritis (NCT06191042 / EUCT 2023-507393-40)